Press Room

News / Nov 12, 2019

Celebration of Hovione’s 60th anniversary in Tokyo

at the Imperial Hotel, Tokyo – 12th November 2019

Celebrating 60th Anniversary in Tokyo | Hovione

On November 12th 2019, Hovione organized a scientific conference held at the Imperial Hotel in Tokyo, to celebrate our 60th anniversary and Filipe Gaspar, VP R&D at Hovione, was the Session Chair.

 

The conference with the title "Accelerating New Medicines to Patients in Need" had the following program:

  • Innovation at Hovione and Hovione Research Program
  • Knowledge Management, Modeling & Simulation
  • Corollary Case-Study - DMF for SDDs
  • Continuous Tableting
  • Fully Integrated Offering – One Site Stop
  • Digital Transformation as an enabler of speed and data quality

The day closed with a cocktail where we joined together clients, friends and stakeholders that make Hovione a great Company.

 

Resources

 

 

Find more about Hovione in Japan

 

 

Also in the Press Room

See All

The global inhalation contract development and manufacturing organization (CDMO) market is projected to grow from USD 9.13 billion in 2025 to USD 16.68 billion by 2035, reflecting a compound annual growth rate (CAGR) of 5.7% during the forecast period. This growth is driven by the increasing prevalence of respiratory diseases, advancements in inhalation drug delivery technologies, and the rising demand for outsourced manufacturing services in the pharmaceutical industry. The inhalation CDMO market has emerged as a pivotal segment in the pharmaceutical contract development and manufacturing industry. With a rising demand for inhaled therapies for conditions like asthma, COPD, and cystic fibrosis, companies are increasingly outsourcing drug development and production to specialized partners. Inhalation CDMO services cater to both large pharmaceutical corporations and small biotech firms, offering expertise in formulation, device compatibility, regulatory support, and scale-up manufacturing. This market is gaining traction due to the complexity of inhalation drug delivery, which often requires niche technical capabilities and specialized equipment. Outsourcing to an inhalation CDMO allows drug developers to reduce time-to-market while ensuring quality and compliance with global standards. (...) Top Companies Several players dominate the inhalation CDMO market through technological expertise, global reach, and service portfolio diversity: (...) Hovione – Offers particle engineering and inhalation development, with a focus on dry powder inhalers. (...) These companies are continually investing in facilities, talent, and technology to meet evolving customer needs in the inhalation CDMO market.   Read the full article on Pharmiweb.com        

Press Clipping

Inhalation CDMO Market Growth Analysis & Forecast 2025 to 2035

Jun 25, 2025